A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503587-17-00

Acronym

MK-4280-003

Enrollment

Registered

2023-10-05

Start date

2019-03-20

Completion date

2025-10-09

Last updated

2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic malignancies

Brief summary

Percentage of Participants Experiencing a Dose-limiting Toxicity (DLT), Percentage of Participants Experiencing an Adverse Event (AE), Percentage of Participants with Treatment Discontinuations Due to an AE

Detailed description

Objective Response Rate (ORR)

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGfavezelimab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of Participants Experiencing a Dose-limiting Toxicity (DLT), Percentage of Participants Experiencing an Adverse Event (AE), Percentage of Participants with Treatment Discontinuations Due to an AE	—

Secondary

Measure	Time frame
Objective Response Rate (ORR)	—

Countries

Germany, Greece, Hungary, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026